Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Oncode Bridge Fund
Deal Size : Undisclosed
Deal Type : Funding
Oncode Institute and ArgoBio Launch Laigo Bio
Details : The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Oncode Bridge Fund
Deal Size : Undisclosed
Deal Type : Funding